Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 84.5 HKD 1.08% Market Closed
Market Cap: 144.8B HKD

Innovent Biologics Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Innovent Biologics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ1.3B
CAGR 3-Years
47%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash from Operating Activities
-ÂĄ527.6m
CAGR 3-Years
19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Cash from Operating Activities
ÂĄ3.1B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ355.1m
CAGR 3-Years
-40%
CAGR 5-Years
5%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Cash from Operating Activities
-ÂĄ429.8m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Innovent Biologics Inc
Glance View

Market Cap
139.7B HKD
Industry
Biotechnology

In the bustling landscape of the biotechnology industry, Innovent Biologics Inc. stands out as a dynamic player committed to advancing precision medicine. Founded in 2011, this Chinese-based company has carved out a significant niche in the development of monoclonal antibodies for oncology, metabolic disorders, and autoimmune diseases. Innovent sought to bridge the gap between innovation and affordability, an ambitious vision fueled by strategic collaborations with global pharma giants and local research centers. The company’s flagship product, Tyvyt (sintilimab), is a testament to their pioneering spirit—a PD-1 inhibitor developed in partnership with Eli Lilly, which gained approval for the treatment of various cancers in China. Innovent leverages its robust in-house R&D capabilities and partnerships to craft an extensive pipeline of potential therapies, positioning itself as a linchpin in the race to address unmet medical needs across its target markets. Innovent Biologics generates revenue through strategic licensing agreements, collaborative development programs, and direct sales of its commercialized therapies. It adopts a multinational partnership model that allows it to both share development costs and tap into broader distribution channels, thus accelerating growth while minimizing financial risk. By focusing on biopharmaceuticals that address prevalent health concerns, Innovent capitalizes on the rising demand for innovative healthcare solutions in China and beyond. Furthermore, the company's vertically integrated infrastructure—from research to commercialization—ensures optimized costs and sustained profitability in a competitive industry landscape. Innovent’s financial trajectory is buoyed by its ability to balance cutting-edge scientific innovation with strategic market positioning, underscoring its reputation as a formidable force in global biotech.

Intrinsic Value
63.58 HKD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Innovent Biologics Inc's Cash from Operating Activities?
Cash from Operating Activities
1.3B CNY

Based on the financial report for Jun 30, 2025, Innovent Biologics Inc's Cash from Operating Activities amounts to 1.3B CNY.

What is Innovent Biologics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
132%

Over the last year, the Cash from Operating Activities growth was 132%.

Back to Top